Trials / Completed
CompletedNCT03187821
Comparison of Superior vs Nasal/Temporal Laser Peripheral Iridotomy in Primary Angle Closure
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 1,000 (actual)
- Sponsor
- Venkatesh Rengaraj · Academic / Other
- Sex
- All
- Age
- 30 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine if location of laser peripheral iridotomy (LPI) that is the standard of care treatment for angle closure glaucoma is related to changes in post-operative intraocular pressure (IOP), endothelial cell count,anterior chamber angle morphology and onset of new visual disturbances.
Detailed description
Study hypothesis: Location of laser peripheral iridotomy affects occurrence of post-operative dysphotopsia symptoms, intraocular pressure, anterior chamber angle morphology and corneal endothelial cell count Study design: Multicenter randomized, prospective, single masked trial Trial setting: Hospitals Trial type: Treatment Interventions: South Indian subjects aged 30 years or greater, with primary angle closure suspect (PACS) or primary angle closure/ primary angle closure glaucoma(PAC/PACG) will be randomized to either bilateral superior or nasal/temporal laser peripheral iridotomy. Subjects will undergo noninvasive testing and imaging studies to measure IOP, anterior chamber angle morphology and endothelial cell count and asked to answer a questionnaire at baseline and again at 2 weeks and 6 months after treatment Primary outcome measures: Occurrence of new self-reported general eye or dysphotopsia symptoms. Secondary outcome measures: intraocular pressure, anterior chamber and anterior chamber angle morphology, endothelial cell count.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Laser peripheral iridotomy | location of laser peripheral iridotomy |
Timeline
- Start date
- 2012-09-01
- Primary completion
- 2014-01-01
- Completion
- 2015-01-01
- First posted
- 2017-06-15
- Last updated
- 2017-06-15
Source: ClinicalTrials.gov record NCT03187821. Inclusion in this directory is not an endorsement.